Effects of Ketones on Muscle Wasting During Caloric Restriction in Lean Females

Because of these anabolic properties of ketone bodies and the fact that ketone bodies prevent muscle protein breakdown for gluconeogenesis during energetic stress, ketone bodies can be a promising strategy to prevent or treat skeletal muscle wasting. Therefore, our aim is to investigate the effect of 3HHB intake on muscle wasting and its adverse consequences during a period of caloric restriction in lean females. In addition, we compare the effects of 3HHB intake with a high protein diet, which is currently considered as the best strategy to minimize lean loss during hypo-energetic periods. To end, we aim to investigate the synergistic effects of the intake of 3HHB in combination with a high protein diet.

Study Overview

• Status: Completed
• Conditions: Ketosis; Protein Intake; Muscle Wasting; Caloric Restriction
• Intervention / Treatment: Drug: Ketone supplementation; Dietary supplement: Increased protein intake

Detailed Description

Thermodynamics state that body mass declines during periods in which energy expenditure exceeds energy intake. This negative energy balance can be obtained either by reducing energy intake, called caloric restriction, by increasing energy expenditure, i.e higher level of physical activity, or the combination of both. The sustained energy deficit results in a net loss of body weight due to losses of both fat and skeletal muscle mass in a ratio of approximately 3:11, depending on the severity of caloric restriction, diet composition and initial body fat percentage. Decreases in muscle mass are due to a combination of downregulated muscle protein synthesis in conjunction with an increased ubiquitin-proteasome-mediated muscle proteolysis, resulting in a negative net protein turnover.

In the context of sports, many athletes try to lose body weight to achieve different goals, such as improving performance by optimizing power-to-weight ratio, competing in a certain body weight category or for aesthetic reasons. However, the loss of body weight is often accompanied by detrimental loss of skeletal muscle mass, which is associated with a myriad of negative consequences including impaired physical performance and increased susceptibility to injury. Hence, athletes undergoing periods of caloric restriction strive for body weight loss via fat loss, while minimizing loss of lean mass. Recent studies have demonstrated that an increased protein intake, higher than the recommended dietary allowance (0.8g/kg/day), attenuates the loss of muscle mass during caloric restriction. Research has shown that the high protein diet has minor effects on muscle proteolysis compared to normal dietary protein but restores muscle protein synthesis, which is probably the primary mechanism by which lean mass is preserved. Specifically, in young healthy athletes, it is shown that a higher protein intake of 1.6-2.4 g per kg body weight per day reduces the loss of muscle mass during short-term caloric restriction periods.

In female athletes, longer periods of low energy availability (with or without an eating disorder) are often interrelated with menstrual dysfunctions and decreased bone mineral density, a syndrome called the 'female athlete triad'. The triad is particularly common in sports that emphasize aesthetics or leanness and can impose lifelong health consequences. However, interventions that minimize loss of lean mass and prevent hormonal and bone metabolism dysregulations in females during periods of caloric restriction, are still missing.

Ketone bodies, i.e. D-β-hydroxybutyrate (βHB), acetoacetate (AcAc) and acetone are naturally occurring chemical compounds synthesized in the liver from circulating fatty acids under conditions of low blood glucose and insulin levels. In normal physiological conditions, the concentration of serum ketone levels remains low (< 0.1 mM). However, during starvation or applying a ketogenic diet, i.e low carbohydrate content, serum concentrations of βHB and AcAc can increase up to 5-8 mM and 1-2 mM, respectively. In these conditions, ketone bodies serve as an alternative and more efficient energy source for various tissues, including the brain, heart and skeletal muscle, thereby 'sparing' the glucose storages. In normal conditions, the brain can only use glucose as an energy fuel to maintain central nervous system functions. Therefore, sparing glucose storages during periods of energetic stress is extremely important for survival. Besides, this sparing of glucose storages prevents the breakdown of muscle proteins which can be used as precursors for gluconeogenesis, providing glucose for the brain and other tissues. Hence, the availability of ketone bodies reduces the breakdown of muscle proteins for gluconeogenesis and, thus, preserves skeletal muscle mass even when energy availability is limited. Therefore, elevating ketone body levels may be an important strategy to prevent skeletal muscle wasting during periods of energetic stress.

Since recently, serum levels of ketone bodies can be increased by the intake of the ketone body ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (3HHB). This orally absorbable ketone body ester is proven safe and well-tolerated in both animals and humans and can elevate ketone body levels within 30 min to 5-6 mM, similar to levels after approximately one week of fasting. The availability of this ketone body ester allows for controlled studies on the effect of ketone bodies on muscle homeostasis without the negative side-effects of starvation and a ketogenic diet, i.e high serum triglyceride and cholesterol levels. The effects of 3HHB on endurance performance is still debated. However, a recent study from our lab showed that post-exercise ingestion of 3HHB increases markers of protein synthesis, which was further confirmed by in vitro experiments. C2C12 myoblasts showed increased leucine-mediated muscle protein synthesis by incubation of physiological concentrations of ketone bodies. Most recently, we found that dietary supplementation with 3HHB substantially improved survival and maintenance of functional capacity and muscular integrity in a mouse model of cancer cachexia.

Because of these anabolic properties of ketone bodies and the fact that ketone bodies prevent muscle protein breakdown for gluconeogenesis during energetic stress, ketone bodies can be a promising strategy to prevent or treat skeletal muscle wasting. Therefore, our aim is to investigate the effect of 3HHB intake on muscle wasting and its adverse consequences during a period of caloric restriction in lean females. In addition, we compare the effects of 3HHB intake with a high protein diet, which is currently considered as the best strategy to minimize lean loss during hypo-energetic periods. To end, we aim to investigate the synergistic effects of the intake of 3HHB in combination with a high protein diet.

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Vlaams-brabant
    • Leuven, Vlaams-brabant, Belgium, 3000
      • KU Leuven

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Females between 18 and 40 years old
• Fat percentage between 16 and 25%
• Regularly involved in physical activity ( > 6 h/week)
• Use of hormonal contraceptives
• Good health status confirmed by a medical screening
• Stable body weight during the last 3 months prior to the study, i.e. no changes > 2 kg

Exclusion Criteria:

• Smoking
• Obsessive pursuit for thinness, evaluated by the Eating Disorder Inventory 3 (EDI-3) 'Pursuit of leanness' (i.e a score higher than 26/32) (see Appendix 5)
• Intake of any medication or nutritional supplement that is proven to affect exercise performance, except oral contraceptives
• Blood donation during the study
• Current participation in another research trial
• Any other argument to believe that the subject is unlikely to successfully complete the full study protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
NO_INTERVENTION: Placebo; Received 10% protein in nutrition + placebo supplement
EXPERIMENTAL: Ketone; Received 10% protein in nutrition + 3x20g B-hydroxybutyrate per day	Drug: Ketone supplementation; Subjects receive either placebo or ketone ester supplementation; Other Names: Placebo vs ketone supplementation
EXPERIMENTAL: High protein; Received 30% protein in nutrition + placebo supplement	Dietary supplement: Increased protein intake; Subjects receive either normal or increased protein intake; Other Names: Normal vs increased protein intake
EXPERIMENTAL: High protein + ketone; Received 30% protein in nutrition + 3x20g B-hydroxybutyrate per day	Drug: Ketone supplementation; Subjects receive either placebo or ketone ester supplementation; Other Names: Placebo vs ketone supplementation; Dietary supplement: Increased protein intake; Subjects receive either normal or increased protein intake; Other Names: Normal vs increased protein intake

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Muscle mass	The amount of muscle mass loss	Muscle mass is measured before and after 4 weeks of caloric restriction

Collaborators and Investigators

• Sponsor: KU Leuven
• Investigators: Study Director: Katrien Koppo, PhD, KU Leuven

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 1, 2018
• Primary Completion (ACTUAL): December 20, 2018
• Study Completion (ACTUAL): June 1, 2019

Study Registration Dates

• First Submitted: January 25, 2021
• First Submitted That Met QC Criteria: February 4, 2021
• First Posted (ACTUAL): February 8, 2021

Study Record Updates

• Last Update Posted (ACTUAL): February 8, 2021
• Last Update Submitted That Met QC Criteria: February 4, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: muscle mass; caloric restriction; resting metabolic rate; ketone ester; β-hydroxybutyrate
• Additional Relevant MeSH Terms: Metabolic Diseases; Nervous System Diseases; Neurologic Manifestations; Nutrition Disorders; Body Weight; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Body Weight Changes; Atrophy; Emaciation; Weight Loss; Muscular Atrophy; Wasting Syndrome; Cachexia
• Other Study ID Numbers: S61133

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Results will be published in internationally peer-reviewed journals

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No